Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
ADC Therapeutics
ADC Therapeutics
Activities:
Research & Development
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
ChargePoint invest in a single-use manufacturing facility to expand product line
The single-use manufacturing facility will become fully operational in June 2024, and will support the company's trio of liquid and powder transfer devices
Innovation in generics: increased efficiency through peptide API synthesis expertise
Leading Swiss pharmaceutical company Bachem explains the benefits of converging LPPS in the manufacturing of gonadotropin-releasing hormone (GnRH) analogues
Bayer HealthCare and Johns Hopkins University to collaborate on new ophthalmic therapies
The partners will work jointly on the discovery and development of innovative drugs for the treatment of serious back-of-the-eye diseases
Berry Global invests to increase production capacity for healthcare products
Berry Global Group has invested in additional assets and manufacturing capabilities to increase its healthcare production capacity by up to 30% across three of its European sites
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Finance
ADC Therapeutics regains compliance with NYSE continued listing standards
ADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs)
Ingredients
Therapeutic: loncastuximab tesirine for diffuse large B-cell lymphoma
Diffuse large B-cell lymphoma (DLBCL) is an aggressive form of blood cancer. Up to 40% of patients will require further lines of treatment as their disease relapses or becomes refractory to first line treatment
Pharmaceutical
FDA approves ADC supported by Sterling
ZYNLONTA has been granted accelerated approval by the FDA for use in adult patients with relapsed or refractory B-cell lymphoma (DLBCL)
Ingredients
Synaffix expands collaboration with ADC Therapeutics
ADC has expanded its existing collaboration to explore additional applications of Synaffix' site-specific conjugation technologies
Ingredients
CRT and University of Copenhagen announce agreement with ADC Therapeutics to develop antibody treatments for cancer
The antibodies target an overexpressed protein on the surface of some cancer cells, which is not expressed on healthy cells
Research & Development
ADC Therapeutics adds eight new members of staff
As the company continues to expand its pipeline of antibody drug conjugates
Research & Development
QMB welcomes ADC Therapeutics as latest tenant
Novel cancer therapy company’s arrival means QMB is almost full
Subscribe now